Ursolic acid induces human hepatoma cell line SMMC-7721 apoptosis via p53-dependent pathway

Chinese Medical Journal

Volumn 123, Issue 14, 2010, Pages 1915-1923

  Yu, Yan Xia ^a,b,c   Gu, Zhen Lun ^a   Yin, Jiang Lin ^b   Chou, Wen Hsien ^a   Kwok, Chi Yi ^a   Qin, Zheng Hong ^a,c   Liang, Zhong Qin ^a,c  

^a Suzhou Institute of Chinese Materia Medica   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

Author keywords

p53; SMMC 7721 cells; Ursolic acid

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; GROWTH DIFFERENTIATION FACTOR 15; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; PROTEIN FOS; PROTEIN P53; SUPEROXIDE DISMUTASE; URSOLIC ACID;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA MICROARRAY; DRUG MECHANISM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; NUCLEOTIDE SEQUENCE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; FLOW CYTOMETRY; HUMANS; LIVER NEOPLASMS; MICROSCOPY, ELECTRON, TRANSMISSION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRITERPENES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78649573167     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.14.016     Document Type: Article

References (52)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Roberts LR, Gores GJ. Emerging drugs for hepatocellular carcinoma. Expert Opin Emerg Drugs 2006; 11: 469-487.
3. Ovesná Z, Vachálková A, Horváthová K, Tóthová D. Pentacyclic triterpenoic acids: new chemoprotective compounds. Neoplasma 2004; 51: 327-333.
4. Liu J. Pharmacology of oleanolic acid and ursolic acid. J Ethnopharmacol 1995; 49: 57-68.
5. Baglin I, Mitaine-Offer AC, Nour M, Tan K, Cavé C, Lacaille-Dubois MA. A review of natural and modified betulinic, ursolic and echinocystic acid derivatives as potential antitumor and anti-HIV agents. Mini Rev Med Chem 2003; 3: 525-539.
6. Tian Z, Lin G, Zheng RX, Huang F, Yang MS, Xiao PG. Anti-hepatoma activity and mechanism of ursolic acid and its derivatives isolated from Aralia decaisneana. World J Gastroenterol 2006; 12: 874-879.
7. Duval RE, Harmand PO, Jayat-Vignoles C, Cook-Moreau J, Pinon A, Delage C, et al. Differential involvement of mitochondria during ursolic acid-induced apoptotic process in HaCaT and M4Beu cells. Oncol Rep 2008; 19: 145-149.
8. Satomi Y, Nishino H, Shibata S. Glycyrrhetinic acid and related compounds induce G1 arrest and apoptosis in human hepatocellular carcinoma HepG2. Anticancer Res 2005; 25: 4043-4047.
9. Li XB, Sun XF, Yin QW, Wang DJ. Ursolic acid inhibits the angiogenesis of transplanted human lung adenocarcinoma cell line A549 in nude mice. J Shandong Univ (Health Sci) 2007; 45: 188-191.
10. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol 2007; 35: 495-516.
11. Harmand PO, Duval R, Delage C, Simon A. Ursolic acid induces apoptosis through mitochondrial intrinsic pathway and caspase-3 activation in M4Beu melanoma cells. Int J Cancer 2005; 114: 1-11.
12. Achiwa Y, Hasegawa K, Komiya T, Udagawa Y. Ursolic acid induces Bax-dependent apoptosis through the caspase-3 pathway in endometrial cancer SNG-II cells. Oncol Rep 2005; 13: 51-57.
13. Hsu YL, Kuo PL, Lin CC. Proliferative inhibition, cell-cycle dysregulation, and induction of apoptosis by ursolic acid in human non-small cell lung cancer A549 cells. Life Sci 2004; 75: 2303-2316.
14. Achiwa Y, Hasegawa K, Udagawa Y. Regulation of the phosphatidylinositol 3-kinase-Akt and the mitogen-activated protein kinase pathways by ursolic acid in human endometrial cancer cells. Biosci Biotechnol Biochem 2007; 71: 31-37.
15. Manu KA, Kuttan G. Ursolic acid induces apoptosis by activating p53 andcaspase-3 gene expressions and suppressing NF-κB mediated activation of bcl-2 in B16F-10 melanoma cells. Int Immunopharmacol 2008; 8: 974-981.
16. Kuribayashi K, El-Deiry WS. Regulation of programmed cell death by the p53 pathway. Adv Exp Med Biol 2008; 615: 201-221.
17. White MK, Cinti C. A morphologic approach to detect apoptosis based on electron microscopy. Methods Mol Biol 2004; 285: 105-111.
18. Mathupala SP, Ko YH, Pedersen PL. Hexokinase II: Cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 2006; 25: 4777-4786.
19. Lu D, Wolfgang CD, Hai T. Activating transcription factor 3, a stress-inducible gene, suppresses Ras-stimulated tumorigenesis. J Biol Chem 2006; 281: 10473-10481.
20. Becker J, Volland S, Noskova I, Schramm A, Schweigerer LL, Wilting J. Keratoepithelin reverts the suppression of tissue factor pathway inhibitor 2 by MYCN in human neuroblastoma: a mechanism to inhibit invasion. Int J Oncol 2008; 32: 235-240.
21. Chang JT, Chan SH, Lin CY, Lin TY, Wang HM, Liao CT, et al. Differentially expressed genes in radioresistant nasopharyngeal cancer cells: gp96 and GDF15. Mol Cancer Ther 2007; 6: 2271-2279.
22. Hendriksen PJ, Dits NF, Kokame K, Veldhoven A, van Weerden WM, Bangma CH, et al. Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res 2006; 66: 5012-5020.
23. Wiener Z, Ontsouka EC, Jakob S, Torgler R, Falus A, Mueller C, et al. Synergistic induction of the Fas (CD95) ligand promoter by Max and NFkappaB in human non-small lung cancer cells. Exp Cell Res 2004; 299: 227-235.
24. Singh RR, Kumar R. MTA family of transcriptional metaregulators in mammary gland morphogenesis and breast cancer. J Mammary Gland Biol Neoplasia 2007; 12: 115-125.
25. Zelko IN, Mariani TJ, Folz RJ. Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. Free Radic Biol Med 2002; 33: 337-349.
26. Rui C, Li C, Xu W, Zhan Y, Li Y, Yang X. Involvement of Egr-1 in HGF-induced elevation of the human 5alpha-R1 gene in human hepatocellular carcinoma cells. Biochem J 2008; 411: 379-386.
27. Williams TM, Lisanti MP. Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol 2005; 288: C494-C506.
28. Novellino L, De Filippo A, Deho P, Perrone F, Pilotti S, Parmiani G, et al. PTPRK negatively regulates transcriptional activity of wild type and mutated oncogenic beta-catenin and affects membrane distribution of beta-catenin/E-cadherin complexes in cancer cells. Cell Signal 2008; 20: 872-883.
29. Zhang H, Wang YS, Han G, Shi Y. TIMP-3 gene transfection suppresses invasive and metastatic capacity of human hepatocarcinoma cell line HCC-7721. Hepatobili Pancreat Dis Int 2007; 6: 487-491.
30. Myatt SS, Lam EW. The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer 2007; 7: 847-859.
31. Derdak Z, Mark NM, Beldi G, Robson SC, Wands JR, Baffy G. The mitochondrial uncoupling protein-2 promotes chemoresistance in cancer cells. Cancer Res 2008; 68: 2813-2819.
32. Milde-Langosch K. The Fos family of transcription factors and their role in tumourigenesis. Eur J Cancer 2005; 41: 2449-2461.
33. Gao K, Lockwood WW, Li J, Lam W, Li G. Genomic analyses identify gene candidates for acquired irinotecan resistance in melanoma cells. Int J Oncol 2008; 32: 1343-1349.
34. Tan M, Wang Y, Guan K, Sun Y. PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway. Proc Natl Acad Sci U S A 2000; 97: 109-114.
35. Piyanuch R, Sukhthankar M, Wandee G, Baek SJ. Berberine, a natural isoquinoline alkaloid, induces NAG-1 and ATF3 expression in human colorectal cancer cells. Cancer Lett 2007; 258: 230-240.
36. Hussain SP, Amstad P, He P, Robles A, Lupold S, Kaneko I, et al. p53-induced up-regulation of MnSOD and GPx but not catalase increases oxidative stress and apoptosis. Cancer Res 2004; 64: 2350-2356.
37. Elkeles A, Juven-Gershon T, Israeli D, Wilder S, Zalcenstein A, Oren M. The c-fos proto-oncogene is a target for transactivation by the p53 tumor suppressor. Mol Cell Biol 1999; 19: 2594-2600.
38. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV, et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999; 285: 1733-1737.
39. Ikeda Y, Murakami A, Ohigashi H. Ursolic acid: an anti-and pro-inflammatory triterpenoid. Mol Nutr Food Res 2008; 52: 26-42.
40. Liu J. Oleanolic acid and ursolic acid: research perspectives. J Ethnopharmacol 2005; 100: 92-94.
41. Novotný L, Vachálková A, Biggs D. Ursolic acid: an anti-tumorigenic and chemopreventive activity. Minireview. Neoplasma 2001; 48: 241-246.
42. Kuribayashi K, El-Deiry WS. Regulation of programmed cell death by the p53 pathway. Adv Exp Med Biol 2008; 615: 201-221.
43. Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis - the p53 network. J Cell Sci 2003; 116: 4077-4085.
44. Einbond LS, Su T, Wu HA, Friedman R, Wang X, Jiang B, et al. Gene expression analysis of the mechanisms whereby black cohosh inhibits human breast cancer cell growth. Anticancer Res 2007; 27: 697-712.
45. Weydert C, Roling B, Liu J, Hinkhouse MM, Ritchie JM, Oberley LW, et al. Suppression of the malignant phenotype in human pancreatic cancer cells by the overexpression of manganese superoxide dismutase. Mol Cancer Ther 2003; 2: 361-369.
46. Milde-Langosch K. The Fos family of transcription factors and their role in tumourigenesis. Eur J Cancer 2005; 41: 2449-2461.
47. Gudkov AV, Komarova EA. Prospective therapeutic applications of p53 inhibitors. Biochem Biophys Res Commun 2005; 331: 726-736.
48. Abd El-Aziz SH, Endo Y, Miyamaori H, Takino T, Sato H. Cleavage of growth differentiation factor 15 (GDF15) by membrane type 1-matrix metalloproteinase abrogates GDF15-mediated suppression of tumor cell growth. Cancer Sci 2007; 98: 1330-1335.
49. Osada M, Park HL, Park MJ, Liu JW, Wu G, Trink B, et al. A p53-type response element in the GDF15 promoter confers high specificity for p53 activation. Biochem Biophys Res Commun 2007; 354: 913-918.
50. Duan H, Zhang HJ, Yang JQ, Oberley LW, Futscher BW, Domann FE. MnSOD up-regulates maspin tumor suppressor gene expression in human breast and prostate cancer cells. Antioxid Redox Signal 2003; 5: 677-688.
51. Zhang C, Gao C, Kawauchi J, Hashimoto Y, Tsuchida N, Kitajima S. Transcriptional activation of the human stress-inducible transcriptional repressor ATF3 gene promoter by p53. Biochem Biophys Res Commun 2002; 297: 1302-1310.
52. Kley N, Chung RY, Fay S, Loeffler JP, Seizinger BR. Repression of the basal c-fos promoter by wild-type p53. Nucleic Acids Res 1992; 20: 4083-4087.